- Home
- Publications
- Publication Search
- Publication Details
Title
Evolution of treatment for rheumatoid arthritis
Authors
Keywords
-
Journal
RHEUMATOLOGY
Volume 51, Issue suppl 6, Pages vi28-vi36
Publisher
Oxford University Press (OUP)
Online
2012-12-06
DOI
10.1093/rheumatology/kes278
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The advent of biosimilar therapies in rheumatology—“O Brave New World”
- (2012) Morton A. Scheinberg et al. Nature Reviews Rheumatology
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
- (2011) D. E. Furst et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
- (2011) Yusuf Yazici et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
- (2011) J. M. Kremer et al. ANNALS OF THE RHEUMATIC DISEASES
- Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate
- (2011) M. C. Genovese et al. ARTHRITIS AND RHEUMATISM
- American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
- (2011) David T. Felson et al. ARTHRITIS AND RHEUMATISM
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
- (2011) Roy Fleischmann et al. ARTHRITIS AND RHEUMATISM
- An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
- (2010) Michael E. Weinblatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
- (2009) Paul Emery et al. ARTHRITIS AND RHEUMATISM
- Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
- (2009) Josef S Smolen et al. LANCET
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
- (2008) R Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
- (2008) E C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
- (2008) Edward Keystone et al. ARTHRITIS AND RHEUMATISM
- Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study
- (2008) Jonathan Kay et al. ARTHRITIS AND RHEUMATISM
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
- (2008) Josef S Smolen et al. LANCET
- Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
- (2008) Paul Emery et al. LANCET
- Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
- (2007) H K Genant et al. ANNALS OF THE RHEUMATIC DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search